# 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

> **NCT00078975** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 26 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** triapine

## Key facts

- **NCT ID:** NCT00078975
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-12
- **Final completion:** 2009-01-07
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078975, "3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00078975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*